After the publication of the recent heart failure (HF) guidelines [1], SGLT2 inhibitors (SGLT2i) were recognized as one of the recommended treatments in patients with HF and reduced ejection fraction (HFrEF) irrespective of the presence of type 2 diabetes mellitus (class I recommendation, level of evidence A) due to the demonstrated reduction in mortality and hospitalization rates in these patients. This evidence concerns the gene SLC5A2 and hydrops fetalis.